Perpetual LTD Regeneron Pharmaceuticals, Inc. Transaction History

Perpetual LTD

$9.23 Trillion
Q3 2024

A detailed history of Perpetual LTD transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Perpetual LTD holds 69,706 shares of REGN stock, worth $51.8 Million. This represents 0.79% of its overall portfolio holdings.

Number of Shares

69,706

Previous 73,525 5.19%

Holding current value

$51.8 Million

Previous $77.3 Billion 5.18%

% of portfolio

0.79%

Previous 0.84%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 09, 2024	SELL	$1024.09 - $1201.76 $3.91 Million - $4.59 Million	-3,819 Reduced 5.19%	69,706 $73.3 Billion
Q2 2024 Jul 30, 2024	SELL	$883.2 - $1071.19 $9.94 Million - $12.1 Million	-11,254 Reduced 13.27%	73,525 $77.3 Billion
Q1 2024 Apr 09, 2024	SELL	$902.69 - $993.35 $13.9 Million - $15.3 Million	-15,440 Reduced 15.41%	84,779 $81.6 Billion
Q4 2023 Feb 15, 2024	SELL	$775.18 - $881.7 $4.91 Million - $5.59 Million	-6,335 Reduced 5.95%	100,219 $88 Billion
Q3 2023 Oct 10, 2023	SELL	$692.45 - $844.37 $5.46 Million - $6.66 Million	-7,883 Reduced 6.89%	106,554 $87.7 Billion
Q2 2023 Jul 13, 2023	SELL	$700.03 - $830.35 $5.06 Million - $6 Million	-7,226 Reduced 5.94%	114,437 $82.2 Billion
Q1 2023 May 08, 2023	BUY	$680.49 - $826.97 $78.7 Million - $95.7 Million	115,710 Added 1943.73%	121,663 $100 Billion
Q3 2020 Dec 08, 2020	SELL	$544.75 - $658.21 $493,543 - $596,338	-906 Reduced 13.21%	5,953 $3.33 Million
Q2 2020 Nov 18, 2020	BUY	$493.32 - $643.92 $154,409 - $201,546	313 Added 4.78%	6,859 $9.02 Million
Q1 2020 Nov 18, 2020	BUY	$336.18 - $494.43 $2.2 Million - $3.24 Million	6,546 New	6,546 $8.53 Million

Others Institutions Holding REGN

# of Institutions

1,531

Shares Held

84.1M

Call Options Held

1.22M

Put Options Held

1.51M

View Full List

About REGENERON PHARMACEUTICALS, INC.

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $79.7B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

More about REGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Perpetual LTD, based on Form 13F filings with the SEC.

News

Stay updated on Perpetual LTD with notifications on news.

Account